Verition Fund Management
NAGE

Verition Fund Management’s Niagen Bioscience NAGE Stock Holding History

Verition Fund Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,066
Closed -$287K – 3769
2025
Q4 		$287K Buy
+45,066
New +$314K ﹤0.01% 3026
2025
Q2 		– Sell
-20,320
Closed -$140K – 3946
2025
Q1 		$140K Sell
20,320
-42,840
-68% -$269K ﹤0.01% 3114
2024
Q4 		$335K Buy
+63,160
New +$346K ﹤0.01% 2717
2021
Q2 		– Sell
-12,125
Closed -$113K – 2191
2021
Q1 		$113K Buy
+12,125
New +$96.1K ﹤0.01% 1421
2018
Q2 		– Sell
-11,416
Closed -$48K – 1370
2018
Q1 		$48K Buy
+11,416
New +$59.8K ﹤0.01% 1078

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Verition Fund Management's NAGE Position: Q1 2026 in Review

Verition Fund Management sold out of Niagen Bioscience (NAGE) in Q1 2026, closing a stake of 45,066 shares — an estimated $287K sold.

Verition Fund Management first reported a position in NAGE in Q1 2018 and held it in 5 quarters. The position peaked at $335K in Q4 2024. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Verition Fund Management reported no remaining Niagen Bioscience position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 45,066 Niagen Bioscience shares in Q1 2026, an estimated $287K.
  • Verition Fund Management first reported a position in Niagen Bioscience in Q1 2018 and held it in 5 quarters.
  • Verition Fund Management's Niagen Bioscience position peaked at $335K in Q4 2024.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.